$SKYE
Skye Bioscience, Inc. Stock $skye

$skye Overview Financials Valuation SEC Filings Company Website

2020 Q3 Form 10-Q Financial Statement

#000164033420002732 Filed on November 06, 2020

Income Statement

Concept	2020 Q3	2019 Q4	2019 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.192M	$1.128M	$990.1K
YoY Change	20.39%	4.41%	1.03%
% of Gross Profit
Research & Development	$346.2K	$715.9K	$513.0K
YoY Change	-32.51%	198.3%	662.37%
% of Gross Profit
Depreciation & Amortization	$370.00	$360.00	$1.100K
YoY Change	-66.36%
% of Gross Profit
Operating Expenses	$1.538M	$1.844M	$1.503M
YoY Change	2.34%	39.66%	43.75%
Operating Profit	-$1.538M		-$1.503M
YoY Change	2.34%		43.75%
Interest Expense	$182.6K	$7.421M	$301.5K
YoY Change	-39.44%	-251.14%
% of Operating Profit
Other Income/Expense, Net	$241.5K		-$3.428M
YoY Change	-107.05%		226.25%
Pretax Income	-$1.297M	$4.852M	-$4.931M
YoY Change	-73.7%	-178.01%	135.22%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income		0.0%
Net Earnings	-$1.297M	$4.852M	-$4.931M
YoY Change	-73.7%	-178.01%	135.22%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.01		-$0.04
Diluted Earnings Per Share	-$0.01	$34.18K	-$0.04
COMMON SHARES
Basic Shares Outstanding	256.8M shares	134.1M shares	133.0M shares
Diluted Shares Outstanding	257.3M shares		133.0M shares

Balance Sheet

Concept	2020 Q3	2019 Q4	2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.225M	$1.830M	$1.319M
YoY Change	220.2%	-1.08%	24.47%
Cash & Equivalents	$4.225M	$1.830M	$1.319M
Short-Term Investments
Other Short-Term Assets	$3.333K	$7.550K	$3.375K
YoY Change	-1.24%	189.38%	-96.93%
Inventory
Prepaid Expenses	$116.2K	$152.7K	$395.4K
Receivables
Other Receivables
Total Short-Term Assets	$4.349M	$1.995M	$1.723M
YoY Change	152.44%	2.1%	48.51%
LONG-TERM ASSETS
Property, Plant & Equipment	$887.00	$1.983K	$2.349K
YoY Change	-62.24%	-42.44%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$887.00	$1.983K	$2.349K
YoY Change	-62.24%	-42.44%	-76.51%
TOTAL ASSETS
Total Short-Term Assets	$4.349M	$1.995M	$1.723M
Total Long-Term Assets	$887.00	$1.983K	$2.349K
Total Assets	$4.350M	$1.997M	$1.725M
YoY Change	152.14%	2.02%	47.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$731.6K	$129.8K	$206.9K
YoY Change	253.56%	732.27%	244.88%
Accrued Expenses	$81.81K	$77.94K
YoY Change		-56.7%
Deferred Revenue
YoY Change
Short-Term Debt	$71.10K	$0.00	$0.00
YoY Change
Long-Term Debt Due	$71.10K
YoY Change
Total Short-Term Liabilities	$1.211M	$970.8K	$14.26M
YoY Change	-91.51%	-93.91%	26.0%
LONG-TERM LIABILITIES
Long-Term Debt	$1.285M	$387.1K	$3.296M
YoY Change	-61.01%	-71.54%
Other Long-Term Liabilities	$0.00	$90.80K	$567.6K
YoY Change	-100.0%	-58.73%
Total Long-Term Liabilities	$1.285M	$477.9K	$3.864M
YoY Change	-66.74%	-69.76%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.211M	$970.8K	$14.26M
Total Long-Term Liabilities	$1.285M	$477.9K	$3.864M
Total Liabilities	$2.496M	$1.449M	$18.13M
YoY Change	-86.23%	-91.73%	60.14%
SHAREHOLDERS EQUITY
Retained Earnings	-$37.23M	-$32.17M	-$37.03M
YoY Change	0.56%	-3.17%
Common Stock	$39.09M	$32.72M	$20.62M
YoY Change	89.52%	85.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.853M	$548.1K	-$16.40M
YoY Change
Total Liabilities & Shareholders Equity	$4.350M	$1.997M	$1.725M
YoY Change	152.14%	2.02%	47.44%

Cashflow Statement

Concept	2020 Q3	2019 Q4	2019 Q3
OPERATING ACTIVITIES
Net Income	-$1.297M	$4.852M	-$4.931M
YoY Change	-73.7%	-178.01%	135.22%
Depreciation, Depletion And Amortization	$370.00	$360.00	$1.100K
YoY Change	-66.36%
Cash From Operating Activities	-$1.974M	-$1.503M	-$4.525M
YoY Change	-56.37%	48.83%	451.79%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		$0.00	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	6.096M	2.014M	3.991M
YoY Change	52.76%	11.26%
NET CHANGE
Cash From Operating Activities	-1.974M	-1.503M	-4.525M
Cash From Investing Activities		0.000	0.000
Cash From Financing Activities	6.096M	2.014M	3.991M
Net Change In Cash	4.122M	510.6K	-534.0K
YoY Change	-871.91%	-36.17%	-34.88%
FREE CASH FLOW
Cash From Operating Activities	-$1.974M	-$1.503M	-$4.525M
Capital Expenditures		$0.00	$0.00
Free Cash Flow		-$1.503M	-$4.525M
YoY Change		48.83%	451.79%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	567606	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	embi	Proceeds From Issuance Of Common Stock And Warrants Net ProceedsFromIssuanceOfCommonStockAndWarrantsNet		USD
	embi	Proceeds From Issuance Of Common Stock And Warrants Net ProceedsFromIssuanceOfCommonStockAndWarrantsNet	854078	USD
CY2020Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4224601	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1829977	USD
CY2020Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	4538	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	4538	USD
CY2020Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	116226	USD
CY2019Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	152695	USD
CY2020Q3	us-gaap	Other Assets Current OtherAssetsCurrent	3333	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	7550	USD
CY2020Q3	us-gaap	Assets Current AssetsCurrent	4348698	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	1994760	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	887	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1983	USD
CY2020Q3	us-gaap	Assets Assets	4349585	USD
CY2019Q4	us-gaap	Assets Assets	1996743	USD
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	731632	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	129809	USD
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q3	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	789694	USD
CY2020Q3	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	21400	USD
CY2019Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	10000	USD
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	81813	USD
CY2020Q3	us-gaap	Short Term Borrowings ShortTermBorrowings	71102	USD
CY2020Q3	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	263830	USD
CY2019Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	387070	USD
CY2019Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	90797	USD
CY2018Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	219453	USD
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	250074	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	182895	USD
CY2019Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	420406	USD
CY2020Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	41149	USD
CY2019Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	410603	USD
CY2018Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	15738913	USD
CY2020Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	38835167	USD
CY2019Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	13737783	USD
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1210926	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	970818	USD
CY2020Q3	us-gaap	Long Term Debt LongTermDebt	45598	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	32538445	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	1853367	USD
CY2020Q3	us-gaap	Liabilities Liabilities	2496218	USD
CY2020Q3	embi	Multidraw Credit Agreement Related Party Noncurrent MultidrawCreditAgreementRelatedPartyNoncurrent	450000	USD
CY2020Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-37231874	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	548058	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-15562252	USD
CY2019Q4	us-gaap	Liabilities Liabilities	1448685	USD
CY2020Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	-27864191	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-32173282	USD
CY2020Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	250074415	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	182895247	shares
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	250074415	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	182895247	shares
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	-11641442	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	-16402461	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	-1702897	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	-3094424	USD
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4349585	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1996743	USD
	embi	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	-433688	USD
	embi	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	-2024660	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5056992	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3798627	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-1296696	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-4931125	USD
	us-gaap	Net Income Loss NetIncomeLoss	-5058592	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-2341660	USD
	us-gaap	Net Income Loss NetIncomeLoss	-3800227	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-14774392	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	990441	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1296696	USD
	us-gaap	Depreciation Depreciation	1096	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	15905290	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-1420236	USD
	us-gaap	Depreciation Depreciation	1096	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	241216	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	514683	USD
	embi	Fair Value Adjustment Of Derivative Liabilities FairValueAdjustmentOfDerivativeLiabilities	433688	USD
	embi	Fair Value Adjustment Of Derivative Liabilities FairValueAdjustmentOfDerivativeLiabilities	2024660	USD
	embi	Fair Value Of Derivative Liability Excess Of Proceeds FairValueOfDerivativeLiabilityExcessOfProceeds	322644	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	402624	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	438964	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-36469	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	302248	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-4217	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	766	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	601823	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	191333	USD
	us-gaap	Increase Decrease In Notes Payable Related Parties Current IncreaseDecreaseInNotesPayableRelatedPartiesCurrent	11400	USD
	embi	Increase Decrease Accrued Interest Due To Related Party IncreaseDecreaseAccruedInterestDueToRelatedParty	81813	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-156576	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	134469	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4268198	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4524712	USD
	embi	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	6085589	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	9301	USD
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	450000	USD
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	3990699	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3990699	USD
	embi	Total Cash Equivalents And Restricted Cash Shown In Consolidated TotalCashEquivalentsAndRestrictedCashShownInConsolidated	1323872	USD
	us-gaap	Interest Paid Net InterestPaidNet	35645	USD
	us-gaap	Interest Paid Net InterestPaidNet	272611	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1600	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	116700	USD
	embi	Proceeds From Pre Funded Warrant Exercises ProceedsFromPreFundedWarrantExercises	10533	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6662822	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	2394624	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-534013	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1834515	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1857885	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4229139	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1323872	USD
	embi	Cash And Cash Equivalents CashAndCashEquivalents	4224601	USD
	embi	Cash And Cash Equivalents CashAndCashEquivalents	1319360	USD
	embi	Supplemental Restricted Cash SupplementalRestrictedCash	4538	USD
	embi	Supplemental Restricted Cash SupplementalRestrictedCash	4512	USD
	embi	Total Cash Equivalents And Restricted Cash Shown In Consolidated TotalCashEquivalentsAndRestrictedCashShownInConsolidated	4229139	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1600	USD
	embi	Exercise Of Warrants ExerciseOfWarrants	26563	USD
	embi	Exercise Of Warrants ExerciseOfWarrants	144375	USD
	embi	Proceeds Allocated To Equity Classified Warrants Issued With Convertible Multi Draw Credit Agreement ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement	716110	USD
	embi	Fair Value Of Compound Derivative Liability Issued With Convertible Multi Draw Credit Agreement FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement	193414	USD
	embi	Beneficial Conversion Feature On Convertible Multi Draw Credit Agreement BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement	1584850	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	171493	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	173084	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	170106	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	64142	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	28709	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	148365	USD
CY2019Q1	embi	Warrants Issued In Connection With Convertible Multi Draw Credit Agreement Related Party Value WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue	716110	USD
CY2019Q1	embi	Beneficial Conversion Feature In Connection With Convertible Multi Draw Credit Agreement Related Party Value BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue	1584850	USD
CY2019Q2	embi	Stock Issued During Period Value Series B Warrant Exercises StockIssuedDuringPeriodValueSeriesBWarrantExercises	144375	USD
CY2020Q1	embi	Stock Issued During Period Value Series B Warrant Exercises StockIssuedDuringPeriodValueSeriesBWarrantExercises	26563	USD
CY2020Q3	embi	Stock Issued During Period Value Common Stock And Warrants StockIssuedDuringPeriodValueCommonStockAndWarrants	6085589	USD
CY2020Q3	embi	Stock Issued During Period Value Exercise Of Pre Funded Warrants StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants	10533	USD
CY2020Q3	embi	Working Capital Deficit WorkingCapitalDeficit	-3137772	USD
	embi	Senior Management Compensation Plan Description SeniorManagementCompensationPlanDescription	During March 2020, the Company approved a plan to defer up to 50% of the members of senior management’s compensation and 100% of the Board of Director and committee fees indefinitely.
CY2020Q3	embi	Senior Management Compensation Plan Description SeniorManagementCompensationPlanDescription	Upon the closing of the August 2020 Financing, the Company’s Board of Directors determined that the Company had been sufficiently financed to pay the deferred salaries and fees, including a 10% retention bonus, to management and the Board in the aggregate amount of $293,078.
CY2019Q4	us-gaap	Advances Fair Value Disclosure AdvancesFairValueDisclosure	1877938	USD
CY2018Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	15958366	USD
CY2020Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1720835	USD
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4931125	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5401484	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5656982	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-433688	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2024660	USD
CY2019Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	501400	USD
CY2019Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	14305389	USD
	embi	Fair Value Of Warrants Issued FairValueOfWarrantsIssued	516058	USD
	embi	Reclassification Of Derivatives To Equity ReclassificationOfDerivativesToEquity	-144375	USD
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0	USD
CY2020Q3	embi	Fair Value Of Shares Underlying Convertible Debt FairValueOfSharesUnderlyingConvertibleDebt	211523	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	325929	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	0.25
CY2020Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	0.25
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	869144	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	0.25
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	148365	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	170106	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	241216	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	514683	USD
CY2020Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	879628	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y7M2D

Files In Submission

Name	View Source	Status
0001640334-20-002732-index-headers.html	Edgar Link	pending
0001640334-20-002732-index.html	Edgar Link	pending
0001640334-20-002732.txt	Edgar Link	pending
0001640334-20-002732-xbrl.zip	Edgar Link	pending
embi-20200930.xml	Edgar Link	completed
embi-20200930.xsd	Edgar Link	pending
embi-20200930_cal.xml	Edgar Link	unprocessable
embi-20200930_def.xml	Edgar Link	unprocessable
embi-20200930_lab.xml	Edgar Link	unprocessable
embi-20200930_pre.xml	Edgar Link	unprocessable
embi_10q.htm	Edgar Link	pending
embi_ex311.htm	Edgar Link	pending
embi_ex312.htm	Edgar Link	pending
embi_ex321.htm	Edgar Link	pending
embi_ex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SKYE
Skye Bioscience, Inc. Stock $skye

2020 Q3 Form 10-Q Financial Statement

#000164033420002732 Filed on November 06, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SKYE Skye Bioscience, Inc. Stock $skye

2020 Q3 Form 10-Q Financial Statement

#000164033420002732 Filed on November 06, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SKYE
Skye Bioscience, Inc. Stock $skye